Generate Biomedicines Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Generate Biomedicines Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Somerville
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GENB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002100782
- EIN
- 83-1630228
Board of directors
-
Frances Arnold · DirectorSince 2026
-
Jane L. Mendillo · DirectorSince 2026
-
Marsha Fanucci · DirectorSince 2026
-
Michael Nally · Director · Chief Executive OfficerSince 2026
-
Nancy A. Simonian · DirectorSince 2026
-
Noubar Afeyan · DirectorSince 2026
-
Paul Gray Parker · DirectorSince 2026
-
Rupert Vessey · DirectorSince 2026
-
Stephane Bancel · DirectorSince 2026
Chief executives
Michael Nally
· Chief Executive Officer
Since February 2026
Board connections
8 of this board's directors also sit on 9 other boards.
- via Noubar Afeyan and Stephane Bancel
- via Marsha Fanucci
- via Frances Arnold
- via Rupert Vessey
- via Noubar Afeyan
- via Frances Arnold
- via Jane L. Mendillo
- via Michael Nally
- via Paul Gray Parker
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $150,300,800
- 12 purchases by 5 insiders
- Sold, last 12 months
- $16,002
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Frances Arnold Director | Open-market sale | −1,000 | $16.00 | $16,002 |
| Mar 4, 2026 | Michael Nally Director, Officer (Chief Executive Officer) | Open-market purchase | +20,000 | $12.00 | $240,000 |
| Mar 2, 2026 | Grous Beth Officer (Chief People Officer) | Open-market purchase | +300 | $16.00 | $4,800 |
| Mar 2, 2026 | Silvers Jason Officer (President & CFO) | Open-market purchase | +500 | $16.00 | $8,000 |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +12,723,940 | — | — |
| Mar 2, 2026 | Michael Nally Director, Officer (Chief Executive Officer) | Derivative conversion | +658,327 | — | — |
| Mar 2, 2026 | Stephane Bancel Director | Derivative conversion | +724,160 | — | — |
| Mar 2, 2026 | Jane L. Mendillo Director | Open-market purchase | +1,500 | $16.00 | $24,000 |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +12,723,940 | — | — |
| Mar 2, 2026 | Silvers Jason Officer (President & CFO) | Open-market purchase | +500 | $16.00 | $8,000 |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +13,702,224 | — | — |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +13,702,224 | — | — |
| Mar 2, 2026 | Silvers Jason Officer (President & CFO) | Open-market purchase | +1,000 | $16.00 | $16,000 |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +987,491 | — | — |
| Mar 2, 2026 | Noubar Afeyan Director, 10% owner | Derivative conversion | +987,491 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.